Most Popular
-
1
Sought by prosecutors: Key man in Yoon presidential couple’s political drama
-
2
First lady to keep low profile as Yoon’s ratings hit new low
-
3
N. Korea jams GPS signals, affecting ships, civilian aircraft: JCS
-
4
Starbucks to open store on North Korea's doorstep
-
5
Top court to review SK chief’s $1b divorce settlement
-
6
[Weekender] AI is silently changing our work: 7 professionals share how
![[Weekender] AI is silently changing our work: 7 professionals share how](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/07/20241107050847_0.jpg&u=)
-
7
Yoon says S. Korea-US alliance will immediately strike NK if it attempts nuclear attack: Newsweek
-
8
Yoon to convene emergency security, economic meeting to discuss Trump's return
-
9
South Korean opposition head hails Trump for Korean Peninsula peace efforts
-
10
Sunken fishing boat's location confirmed; fishing net hinders search
![[Weekender] AI is silently changing our work: 7 professionals share how](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/07/20241107050847_0.jpg&u=)
[THE INVESTOR] Four South Korean venture capital firms have decided to invest US$16 million in a UK-based cancer drug maker Celleron Therapeutics, according to sources on Oct. 14.
Korea Investment Partners will invest US$6 million while three others including NHN Investment will commit a total of US$10 million into the company developing personalized medicine for cancer patients.
The move marks the first time that Korean venture capital firms are funding a British biotech startup.
As valuations of local biopharma companies have been growing at a rapid clip since last year, domestic investors are turning their eyes to foreign firms, especially those in the UK to benefits from the weak pound that has plunged after the Brexit vote.
Celleron Therapeutics, founded by professors at the University of Oxford, is expected to use the funds for phase 2 clinical trials of its personalized cancer treatment CXD101.
The phase 1 clinical trials showed that it has favorable safety and tolerability in the patients with advanced treatment-resistant aggressive disease, according to the firm.
If it completes the phase 2 clinical trials, a Korean pharmaceutical company which also invested in Celleron Therapeutics plans to enter into an exclusive partnership to commercialize the drug in East Asia.
By Park Han-na (hnpark@heraldcorp.com)
Korea Investment Partners will invest US$6 million while three others including NHN Investment will commit a total of US$10 million into the company developing personalized medicine for cancer patients.
The move marks the first time that Korean venture capital firms are funding a British biotech startup.
As valuations of local biopharma companies have been growing at a rapid clip since last year, domestic investors are turning their eyes to foreign firms, especially those in the UK to benefits from the weak pound that has plunged after the Brexit vote.
Celleron Therapeutics, founded by professors at the University of Oxford, is expected to use the funds for phase 2 clinical trials of its personalized cancer treatment CXD101.
The phase 1 clinical trials showed that it has favorable safety and tolerability in the patients with advanced treatment-resistant aggressive disease, according to the firm.
If it completes the phase 2 clinical trials, a Korean pharmaceutical company which also invested in Celleron Therapeutics plans to enter into an exclusive partnership to commercialize the drug in East Asia.
By Park Han-na (hnpark@heraldcorp.com)
![[Weekender] AI is silently changing our work: 7 professionals share how](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/07/20241107050847_0.jpg&u=)
